for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Acasti Pharma Inc

ACST.OQ

Latest Trade

2.18USD

Change

0.04(+1.87%)

Volume

153,606

Today's Range

2.12

 - 

2.19

52 Week Range

0.61

 - 

2.95

As of on the TSX Venture Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
2.14
Open
2.15
Volume
153,606
3M AVG Volume
3.68
Today's High
2.19
Today's Low
2.12
52 Week High
2.95
52 Week Low
0.61
Shares Out (MIL)
85.19
Market Cap (MIL)
240.23
Forward P/E
-8.55
Dividend (Yield %)
--

Next Event

Q2 2020 Acasti Pharma Inc Earnings Release

Latest Developments

More

Acasti Pharma Inc - QTRLY Loss Per Share $0.15

Neptune Wellness Solutions Inc Says Now Holds About 3 Million Shares Of Acasti Pharma, Representing 3.8% Of The Outstanding Shares Of The Acasti Pharma.

Acasti Pharma Provides Update on Trilogy 2 Trial

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Acasti Pharma Inc

Acasti Pharma Inc is a Canada-based biopharmaceutical company. The Company is focused on the research, development and commercialization of prescription drugs using omega 3 fatty acids (OM3s) derived from krill oil. OM3s has clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia (HTG). The Company's drug candidate is CaPre, an OM3 phospholipid, which is being developed for the treatment of severe hypertriglyceridemia, a condition characterized by abnormally high levels of triglycerides in the bloodstream (over 500 mg/dL) (severe hypertriglyceridemia or severe HTG).

Industry

Biotechnology & Drugs

Contact Info

545 Prom du Centropolis Suite 100

+1.450.6864555

https://www.acastipharma.com/

Executive Leadership

Roderick Noel Carter

Executive Chairman of the Board

Janelle D'Alvise

President, Chief Executive Officer, Director

Linda Parinella O'Keefe

Chief Financial Officer

Pierre Lemieux

Chief Operating Officer

Jean-Francois Boily

Vice President - Finance

Key Stats

2.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, CAD)

2019

0.0K

2020(E)

0.0K
EPS (CAD)

2017

-0.970

2019

-0.950

2020(E)

-0.265
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
62.50
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
52.34
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-296.42
Return on Equity (TTM)
-170.80

Latest News

Latest News

BRIEF-Acasti Pharma Files For Mixed Shelf Of Up To $50 Mln

* ACASTI PHARMA INC FILES FOR MIXED SHELF OF UP TO $50 MILLION - SEC FILING Source text: (http://bit.ly/2tmbRjP) Further company coverage:

BRIEF-Acasti Pharma Q3 ‍net Loss 2017 Was $0.40 Per Share​

* ACASTI PHARMA REPORTS THIRD QUARTER FY 2018 FINANCIAL RESULTS

BRIEF-Acasti Pharma grants Chinese pharma co exclusive license to commercialize CaPre in China​

* Acasti Pharma Inc - clarifies term of proposed strategic partnership with China pharmaceutical company

BRIEF-Acasti Pharma ‍enters into non-binding agreement with China-based pharma

* Acasti Pharma Inc - entered into a non-binding term sheet with a China-based pharmaceutical company

BRIEF-Acasti Pharma says is offering 11.7 mln common shares

* Says it is offering 11.7 million common shares - SEC Filing Source text: (http://bit.ly/2mBXlkS) Further company coverage:

BRIEF-Acasti Pharma reports Q2 loss per share C‍$0.31​

* Acasti Pharma reports second quarter FY 2018 financial results

BRIEF-Acasti Pharma files for offering of up to $17.25 mln of common stock

* Acasti Pharma Inc files for offering of up to $17.25 million of common stock - sec filing Source text : http://bit.ly/2yN6Pf7 Further company coverage:

BRIEF-Acasti Pharma reports Q1 loss per share c$0.19

* Acasti Pharma reports first quarter fy 2018 financial results

BRIEF-Acasti Pharma issues common shares in payment of outstanding interest under debentures

* Acasti Pharma announces issuance of common shares in payment of outstanding interest under debentures Source text for Eikon: Further company coverage:

BRIEF-Acasti Pharma reports Q4 and FY 2017 financial results

* Acasti Pharma reports fourth quarter and full-year 2017 financial results

BRIEF-Acasti Pharma, CordenPharma announce large scale production of CaPre with new continuous manufacturing process

* Acasti Pharma and CordenPharma announce large scale production of Capre with new continuous manufacturing process Source text for Eikon: Further company coverage:

BRIEF-Acasti Pharma says has successfully completed two Phase 1, two Phase 2 clinical trials with Capre

* Acasti Pharma Inc - has successfully completed two Phase 1 and two Phase 2 clinical trials with Capre for treatment of hypertriglyceridemia

BRIEF-Acasti Pharma provides update on Capre phase 3 development program

* Acasti Pharma provides update on Capre phase 3 development program

BRIEF-Acasti Pharma announces pricing for its public offering of units

* Acasti Pharma announces pricing for its public offering of units

BRIEF-Acasti Pharma Q3 loss C$0.22/shr

* Acasti pharma - Had cash,short-term investments of $5.8 million as of Nov 30, 2016

BRIEF-Acasti Pharma appoints Linda O'keefe as chief financial officer

* Acasti Pharma appoints Linda O'keefe as chief financial officer

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up